Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

Patients and healthy controls from different geographical regions in Brazil.

Samples were collected from 122 VL patients, 64 VL-AIDS patients, and 83 healthy individuals living in endemic areas. n—number of samples; VL—visceral leishmaniasis; VL-AIDS—co-infection; HC—healthy controls. The base map was obtained from https://apps.nationalmap.gov/viewer/.

More »

Fig 1 Expand

Fig 2.

Receiver operating characteristic (ROC) curves to determine ELISA performance.

ROC curves were constructed using the values of ABS% Positive obtained from testing samples of VL patients (n = 90) and healthy endemic controls (n = 90) (Panel 1).

More »

Fig 2 Expand

Fig 3.

Percentage of absorbance of the positive standard (ABS% Positive) obtained by ELISA using recombinant antigens in sera from VL patients and healthy controls (Panel 1).

The horizontal black lines represent the median ABS% Positive Control values with a 95% confidence interval. Friedman test: p < 0.0001 (VL patients and Healthy controls). Dunn’s multiple comparisons test: VL patients: **—p = 0.0049; ***—p = 0.0002; ****—p < 0.0001. Healthy controls: **—p = 0.0044 (rK28 x rK39) and p = 0.0013 (rK18 x rK39); ****—< 0.0001; ns—p = 0.0517 (rK39 x rKR95) and p > 0.9999 (rK28 x rKR95).

More »

Fig 3 Expand

Table 1.

Diagnostic performance parameters obtained by ELISA with recombinant antigens determined by ROC curves (Panel 1).

More »

Table 1 Expand

Fig 4.

Reactivity indices obtained by ELISA with recombinant antigens with 122 samples from VL patients, 64 samples from VL / AIDS patients, 83 samples from healthy controls (Panel 2), and 190 samples from patients with other diseases (Panel 3).

The horizontal black lines represent the median ABS% Positive Control values with a 95% confidence interval. Friedman test: p < 0.0001 (for the four groups of samples). Dunn’s multiple comparisons test: VL patients: *—p = 0.0282; ***—p = 0.0004; ****—p < 0.0001; ns—p = 0.2522 (rK18 x rKR95) and p = 0.3187 (rK28 x rK18). VL / AIDS patients: *—p = 0.0300; **—p = 0.0077; ****—p < 0.0001; ns—p = 0.6920 (rK28 x rK18), p > 0.9999 (rk28 x rKR95) and p = 0,2825 (rK39 x rKR95). Healthy controls: *—p = 0.0374; ***—p = 0.0003; ****—p < 0.0001; ns—p = 0.4002 (rK28 x rKR95) and p = 0.1692 (rK39 x rKR95). Other diseases patients: *—p = 0.0152; ****—p < 0.0001; ns—p = 0.1646 (rK28 x rK39) and p > 0.9999 (rK39 x rKR95). The four antigens discriminated significantly between negative (healthy controls) and positive (VL patients) samples (Mann-Whitney test: p < 0.0001).

More »

Fig 4 Expand

Fig 5.

Reactivity indices obtained by rK28-ELISA, rK39-ELISA, rK18-ELISA, and rKR95-ELISA with 122 samples from VL patients, 83 samples from healthy controls, 190 samples from patients with other diseases, and 64 samples from VL / AIDS patients.

The horizontal black lines represent the median ABS% Positive Control values with a 95% confidence interval. Kruskal-Wallis’s: p < 0.0001 (for the four antigens). Dunn’s multiple comparisons test: rK28: *—p = 0.0327; ****—p < 0.0001; ns—p = 0.6551. rK39: *—p = 0.0262; ****—p < 0.0001; ns—p = 0.0515. rK18: **—p = 0.0025; ***—p = 0.0003; ****—p < 0.0001; ns—p > 0.9999. rKR95: ****—p < 0.0001; ns—p > 0.9999 (control x other diseases) and p = 0.1357 (VL x VL / AIDS).

More »

Fig 5 Expand

Table 2.

Performance obtained by rK18-ELISA, rK28-ELISA, rK39-ELISA, and rKR95-ELISA in sera from VL patients, VL / AIDS patients, healthy controls (Panel 2), and patients with other diseases (Panel 3).

More »

Table 2 Expand

Fig 6.

Antigen-specific antibodies in sera patients with potentially confounding infectious diseases (Panel 3) developed for recombinant antigens.

The horizontal black lines represent the median ABS% Positive Control values with a 95% confidence interval. Friedman test (p values are in the graphic for each disease), followed by Dunn’s multiple comparisons test: Cutaneous leishmaniasis: **—p = 0.0038; ***—p = 0.0002. Malaria: *—p = 0.0342 (rK28 x rK18) and p = 0.0170 (rK18 x rKR95); **—p = 0.0011. Mucosal leishmaniasis: *—p = 0.0325; ***—p = 0.0002. Paracoccidioidomycosis: *—p = 0.0225 (r18 x rKR95) and p = 0.0368 (rK28 x rKR95); ****—p < 0.0001. Syphilis: *—p = 0.0291. Toxoplasmosis: *—p = 0.0351; **—p = 0.0057; ***—p = 0.0001. Tuberculosis: *—p = 0.0207; ***—p = 0.0003.

More »

Fig 6 Expand